A Phase IIa, Double-blind, Randomised, Parallel-group, Multi-centre Study to Evaluate the Analgesic Efficacy of 28 days' Oral Administration of AZD2423 Compared with Placebo in Patients with Painful Diabetic Polyneuropathy.
Latest Information Update: 21 Apr 2011
At a glance
- Drugs AZD 2423 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors AstraZeneca
Most Recent Events
- 30 Apr 2010 New trial record